Beam Therapeutics (BEAM) Net Income towards Common Stockholders (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$94.3 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 12.93% year-over-year to -$94.3 million in Q1 2026; TTM through Mar 2026 was -$65.0 million, a 83.17% increase from a year earlier, with the FY2025 full-year figure at -$80.0 million, up 78.77% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$94.3 million, down from $244.3 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for BEAM reached as high as $244.3 million in Q4 2025 and fell as low as -$112.7 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$57.2 million across 5 years, with a median of -$94.3 million in 2026.
• Across the five-year window, Net Income towards Common Stockholders sank 289.7% in 2022 and surged 472.36% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$38.3 million in 2022, then jumped by 472.36% to $142.8 million in 2023, then sank by 163.27% to -$90.4 million in 2024, then surged by 370.38% to $244.3 million in 2025, then tumbled by 138.61% to -$94.3 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$94.3 million in Q1 2026, $244.3 million in Q4 2025, and -$112.7 million in Q3 2025.